A Somatic Mutation of the KEAP1 Gene in Malignant Melanoma Is Involved in Aberrant NRF2 Activation and an Increase in Intrinsic Drug Resistance
- 1 February 2014
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (2) , 553-556
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 15 references indexed in Scilit:
- Drug-Induced Oxidative Stress and ToxicityJournal of Toxicology, 2012
- Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolutionGenes to Cells, 2011
- Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 InhibitionJournal of Biological Chemistry, 2010
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProceedings of the National Academy of Sciences, 2010
- Acral Lentiginous MelanomaArchives of Dermatology, 2009
- Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder CancerGastroenterology, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation FrequenciesClinical Cancer Research, 2006
- Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomasProceedings of the National Academy of Sciences, 2006
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002